The US Food and Drug Administration has approved a new once-daily pill for a difficult form of advanced breast cancer, giving patients another option for the point when standard hormone therapy stops working.
The drug, giredestrant, will be sold under the brand name Wilserdly. According to Roche, whose Genentech unit developed it, the approval covers adults with oestrogen receptor-positive, HER2-negative breast cancer that has spread or can't be removed by surgery — specifically when the tumour carries a mutation in a gene called ESR1 and the disease has come back or got worse during or after hormone-based treatment.
A treatment for when hormone therapy stops working
For many people with this type of breast cancer, hormone therapy is the backbone of treatment. It works by blocking oestrogen, which feeds the tumour. The trouble is that tumours can learn to dodge it. Roche estimates that up to 40% of patients with hormone receptor-positive metastatic breast cancer develop ESR1 mutations, which drive resistance and let the disease progress.
Wilserdly belongs to a newer class of medicines known as oral SERDs — selective oestrogen receptor degraders. Rather than just blocking the oestrogen receptor, the drug breaks it down, shutting off the signal that helps certain breast cancers grow. Taken as a tablet alongside an existing drug called everolimus, it gives doctors an all-oral combination for patients who have already been through a CDK4/6 inhibitor and hormone therapy.
What the trial showed
The approval rests on results from a large international trial called evERA, published in the New England Journal of Medicine. In that study, researchers compared Wilserdly plus everolimus against standard hormone therapy plus everolimus in patients whose cancer had already been treated with a CDK4/6 inhibitor.
Among patients whose tumours carried the ESR1 mutation, the Wilserdly combination cut the risk of the disease progressing or the patient dying by 62% compared with the standard combination, according to the trial results. Roche described it as the first next-generation oral SERD combination to beat standard hormone therapy head-to-head in this setting.
Genentech said the drug should be available in the United States in the coming weeks. Roche told Reuters the treatment will be priced at $22,500 per month, a figure that is likely to draw scrutiny from patient groups and insurers as the drug reaches clinics.
What it costs, and what's next
The approval is only the first step for Wilserdly. Roche has also asked the FDA to approve the drug as a follow-up treatment after surgery for early-stage breast cancer, for patients at intermediate to high risk of the disease coming back. That application was accepted under the FDA's priority review programme, with a decision expected by 30 November.
The early-stage case is built on a separate trial, lidERA, involving around 4,100 patients. In that study, the drug reduced the risk of the cancer returning or the patient dying by 30% compared with standard hormone therapy, with three-year invasive disease-free survival of 92.4% against 89.6%.
For now, though, the approval matters most to people living with advanced disease that has stopped responding to the treatments they have already tried. Anyone affected should speak to their oncologist about whether the new option fits their own diagnosis, including whether their tumour has been tested for the ESR1 mutation.
